BR112022009974A2 - Métodos de produção de um polímero ou micropartículas revestidas com polímero, para produzir microesferas poliméricas ou revestidas com polímero e para produzir micropartículas, composição de liberação sustentada, micropartículas, e, composição farmacêutica - Google Patents

Métodos de produção de um polímero ou micropartículas revestidas com polímero, para produzir microesferas poliméricas ou revestidas com polímero e para produzir micropartículas, composição de liberação sustentada, micropartículas, e, composição farmacêutica

Info

Publication number
BR112022009974A2
BR112022009974A2 BR112022009974A BR112022009974A BR112022009974A2 BR 112022009974 A2 BR112022009974 A2 BR 112022009974A2 BR 112022009974 A BR112022009974 A BR 112022009974A BR 112022009974 A BR112022009974 A BR 112022009974A BR 112022009974 A2 BR112022009974 A2 BR 112022009974A2
Authority
BR
Brazil
Prior art keywords
polymer
microparticles
coated
produce
solution
Prior art date
Application number
BR112022009974A
Other languages
English (en)
Inventor
Zhao Yiming
Chen Hunter
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112022009974A2 publication Critical patent/BR112022009974A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Métodos de emulsão não aquosa para a produção de micropartículas poliméricas ou revestidas com polímero são providos. Um método produz uma composição de micropartículas de liberação sustentada combinando proteína em pó e um polímero em um solvente de hidrocarboneto para formar uma primeira solução não aquosa e adicionar a primeira solução a uma segunda solução, em que a segunda solução compreende um líquido de fluorocarboneto e um fluorotensoativo para formar uma emulsão não aquosa compreendendo múltiplas gotículas de hidrocarboneto de emulsão no líquido de fluorocarboneto. O processo de endurecimento de micropartículas subsequente inclui as etapas de remoção do solvente de hidrocarboneto das gotículas de emulsão formadas, que podem ser alcançadas através da evaporação do hidrocarboneto na condição ambiente sob agitação, ou endurecimento acelerado por meio do vácuo, ou por meio da adição de hidrofluoroéster no fluorocarboneto como um cossolvente. Remover o líquido de fluorocarboneto e lavar com líquido de fluorocarboneto extra para isolar as micropartículas de liberação sustentada, em que as micropartículas de liberação sustentada compreendem um ou mais núcleos de proteína e um córtex de polímero.
BR112022009974A 2019-11-25 2020-11-25 Métodos de produção de um polímero ou micropartículas revestidas com polímero, para produzir microesferas poliméricas ou revestidas com polímero e para produzir micropartículas, composição de liberação sustentada, micropartículas, e, composição farmacêutica BR112022009974A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962940009P 2019-11-25 2019-11-25
PCT/US2020/062228 WO2021108548A1 (en) 2019-11-25 2020-11-25 Sustained release formulations using non-aqueous emulsions

Publications (1)

Publication Number Publication Date
BR112022009974A2 true BR112022009974A2 (pt) 2022-08-16

Family

ID=73943344

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009974A BR112022009974A2 (pt) 2019-11-25 2020-11-25 Métodos de produção de um polímero ou micropartículas revestidas com polímero, para produzir microesferas poliméricas ou revestidas com polímero e para produzir micropartículas, composição de liberação sustentada, micropartículas, e, composição farmacêutica

Country Status (13)

Country Link
US (2) US11730793B2 (pt)
EP (1) EP4065086A1 (pt)
JP (1) JP2023502500A (pt)
KR (1) KR20220104797A (pt)
CN (1) CN114760986A (pt)
AU (1) AU2020394428A1 (pt)
BR (1) BR112022009974A2 (pt)
CA (1) CA3158119A1 (pt)
CO (1) CO2022008679A2 (pt)
IL (1) IL293112A (pt)
MX (1) MX2022006236A (pt)
WO (1) WO2021108548A1 (pt)
ZA (1) ZA202206381B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116940347A (zh) * 2020-11-25 2023-10-24 里珍纳龙药品有限公司 使用非水性膜乳化的持续释放调配物

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210529A (en) 1974-12-26 1980-07-01 Midwest Research Institute Blood compatible polymers and applications thereof
US4304767A (en) 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4764364A (en) 1986-02-25 1988-08-16 S R I International Method of preparing bioerodible polymers having pH sensitivity in the acid range and resulting product
US6063910A (en) 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
JP2651320B2 (ja) 1992-07-16 1997-09-10 田辺製薬株式会社 徐放性マイクロスフェア製剤の製造方法
US5968543A (en) 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6479065B2 (en) * 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US7197120B2 (en) 2000-12-22 2007-03-27 Openwave Systems Inc. Method and system for facilitating mediated communication
AU2002322295C1 (en) 2001-06-21 2008-12-18 Altus Pharmaceuticals Inc. Spherical protein particles and methods of making and using them
DE60309238T2 (de) 2002-03-08 2007-06-06 Asml Netherlands B.V. Lithographische Maske, lithographischer Apparat und Verfahren zur Herstellung einer Vorrichtung
CN1289066C (zh) 2003-09-18 2006-12-13 中国人民解放军第二军医大学 胰高血糖素样肽－1缓释微球制剂及其用途
CN100528224C (zh) 2004-09-27 2009-08-19 中国人民解放军军事医学科学院毒物药物研究所 含干扰素α-1b的注射用缓释微球及其制备方法
CN100475264C (zh) 2004-09-28 2009-04-08 中国人民解放军军事医学科学院毒物药物研究所 含干扰素或其类似物的注射用缓释微球及其制备方法
CN1965809A (zh) 2005-11-16 2007-05-23 中国人民解放军军事医学科学院毒物药物研究所 Lhrh拮抗剂类物质的注射用缓释微球及其制备方法
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CN101809037B (zh) 2007-07-31 2014-01-15 瑞泽恩制药公司 人cd20的人抗体及其使用方法
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CA2766220C (en) 2009-06-26 2021-02-09 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
CN102233129B (zh) 2010-04-29 2014-07-09 上海交通大学 一种预防或治疗视网膜损伤的长效缓释制剂及其制备方法
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
CA2813587C (en) 2010-10-06 2019-01-15 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
KR102048189B1 (ko) 2011-11-14 2019-11-25 리제너론 파아마슈티컬스, 인크. Ｇｄｆ8 및/또는 액티빈 ａ를 특이적으로 길항함으로써 근육량과 근육 강도를 증가시키는 조성물 및 방법
RU2768492C2 (ru) * 2011-11-18 2022-03-24 Ридженерон Фармасьютикалз, Инк. Полимерные белковые микрочастицы
NZ627859A (en) 2012-01-23 2015-09-25 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
WO2014028354A1 (en) 2012-08-13 2014-02-20 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 antibodies with ph-dependent binding characteristics
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
CA2904377C (en) 2013-03-15 2021-07-13 Regeneron Pharmaceuticals, Inc. Il-33 antagonists and uses thereof
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
WO2015138460A1 (en) 2014-03-11 2015-09-17 Regeneron Pharmaceuticals, Inc. Anti-egfrviii antibodies and uses thereof
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EP3636073B1 (en) 2014-05-05 2023-11-15 Regeneron Pharmaceuticals, Inc. Humanized c5 and c3 animals
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
BR112017005110A2 (pt) 2014-09-16 2018-01-23 Regeneron Pharma anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença.
US20160083345A1 (en) 2014-09-19 2016-03-24 Cadila Healthcare Limited Polymorphic forms of lomitapide and its salts and processes for their preparation
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
DK3389636T3 (da) * 2015-12-16 2022-09-19 Regeneron Pharma Sammensætninger og fremgangsmåder til fremstilling af proteinmikropartikler
CN105878191B (zh) * 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 缓释微粒的制备方法、制得的缓释微粒及其应用

Also Published As

Publication number Publication date
US11730793B2 (en) 2023-08-22
MX2022006236A (es) 2022-06-22
IL293112A (en) 2022-07-01
KR20220104797A (ko) 2022-07-26
ZA202206381B (en) 2023-11-29
CN114760986A (zh) 2022-07-15
JP2023502500A (ja) 2023-01-24
EP4065086A1 (en) 2022-10-05
WO2021108548A1 (en) 2021-06-03
CA3158119A1 (en) 2021-06-03
CO2022008679A2 (es) 2022-07-19
US20230414716A1 (en) 2023-12-28
US20220008505A1 (en) 2022-01-13
AU2020394428A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
BR112017027610A2 (pt) processo e aparelho para tratamento de água, e, uso.
BR0313251A (pt) Métodos de extração de polìmero
BR112018006492A2 (pt) composição, artigo fabricado, processo para preparar
BR112015031094A2 (pt) células progenitoras renais
BR112022009974A2 (pt) Métodos de produção de um polímero ou micropartículas revestidas com polímero, para produzir microesferas poliméricas ou revestidas com polímero e para produzir micropartículas, composição de liberação sustentada, micropartículas, e, composição farmacêutica
BR112018074915A2 (pt) composições de revestimento baseadas em pai
BR112017000029A2 (pt) processos melhorados para recuperar componentes valiosos de um processo pirólise rápida catalítica
BR112017014831A2 (pt) processo para produção de polímeros à base de dimetiltaurato de acriloíla, monômeros neutros e monômeros com grupos carboxilato
BR112013024745A2 (pt) camada de revestimento, e método para formar uma camada de revestimento
BR112012029644A2 (pt) composições de decapagem e métodos de realizar e usar os mesmos
BR112016028385A2 (pt) método e sistema para reduzir uma concentração de solvente em uma pluralidade de micropartículas, método para preparar uma pluralidade de microesferas biodegradáveis com um agente medicinalmente ativo, e, composição.
BR112018014029A2 (pt) composição líquida compreendendo um polímero múltiplas fases e um monômero (met) acrílico, seu método de preparação e uso
BR112016028489A2 (pt) um processo melhorado para produzir composições poliméricas peletizadas
BR112018076542A2 (pt) método para preparar partículas contendo celulose
CL2016001375A1 (es) Composición, que comprende agente bioactivo (inmunógeno) dispersado en gotitas de aceite, polímero de recubrimiento entérico, un polímero mucoadhesivo, su método de preparación y uso para la administración oral de un agente bioactivo.
BR112013003845A2 (pt) "método de limpeza de objetos com duas imersões"
BRPI0519139A2 (pt) liberaÇço controlada de entidades biolàgicas
BR112013012693A2 (pt) "processo para produzir misturas de polímero"
RU2018138121A (ru) Способ приготовления наночастицы активного ингредиента с использованием липида в качестве смазывающего вещества в процессе помола
BR112018008405A2 (pt) método para preparar micropartículas de polímero com uma estrutura de rede, e, micropartículas de polímero com uma estrutura de rede.
BR112021020853A2 (pt) Processo de reciclagem
BR112018006481A2 (pt) "método para produzir uma composição de polímero oco, composição de polímero oco, e, dispersão não aquosa"
BR112015016824A2 (pt) método para produzir um sistema catalítico, processo de polimerização e produto polimérico
BR112019000972A2 (pt) processo para preparar filamento de ácido poliláctico de alta resistência
BR112015024541A2 (pt) processo de rejuvenescimento de um catalisador de hidrotratamento usado